The current UK private TRT market runs on ad-hoc tooling.
NHS testosterone thresholds and capacity mean symptomatic men whose results fall in the borderline band are often left outside the treatment pathway; the private market that serves them runs on ad-hoc tooling, with no operator-grade software underneath the category.
Why platform-first matters. Multi-tenant from day one means a clinical lead’s practice runs on the same OS as the next clinic’s; every clinical decision carries a timestamped, attributable record in an append-only audit log, so inspection preparation stops being an archaeology project; AI-clinician handoff means scale without compromising the regulated bottleneck.
Honest framing. This is a market hypothesis, not a market analysis. The page does not claim to know the size; it claims to know the shape.